Caitlin Rausch

31PUBLICATIONS
68CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)AutoimmunityHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Medical virology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (31)

|Jun 27, 2026
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

|May 17, 2026
Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL.

|Apr 26, 2026
Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity-Score Analysis.

|Apr 26, 2026
Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.

|Apr 24, 2026
Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis.

|Oct 22, 2025
Cladribine and venetoclax combined with alemtuzumab in patients with relapsed/refractory T-cell prolymphocytic leukemia.

Naszrin Arani, Caitlin R Rausch, Alexis Geppner

Pageof 6

Frequent Collaborators

21 joint publications

Tapan M Kadia

20 joint publications

Hagop M Kantarjian

17 joint publications

Courtney DiNardo

15 joint publications

Naval G Daver